CBT102-A is under clinical development by CommBio Therapeutics and currently in Phase I for Phenylketonuria (PKU). According to GlobalData, Phase I drugs for Phenylketonuria (PKU) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CBT102-A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CBT102-A overview

Gene therapy is under development for the treatment of phenylketonuria. The therapeutic candidate comprises engineered bacteria expressing phenylalanine hydroxylase (PAH) and is administered through oral route.

CommBio Therapeutics overview

CommBio Therapeutics (CommBio Therapeutics) discovers and develops treatments for diseases caused due to intestinal dysfunction. The company is investigating bacterial vector gene therapies for the treatment of cancer, autoimmune and metabolic diseases. It develops treatment strategies that modulate gut function and correspond to disease signals through genetically engineered bacteria. CommBio Therapeutics utilizes bacterial vector gene therapy drug discovery and development platforms to develop therapies. The company seeks to work in collaboration with academic scientists, clinicians, biotechnology and pharmaceutical companies. It was funded by Med-Fund Capital, ZhangJiang Venture, Hangzhou Grand Biologic Pharmaceutical. CommBio Therapeutics is headquartered Shanghai, China.

For a complete picture of CBT102-A’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.